menu search

SVRA / Savara: A Speculative Play

Savara: A Speculative Play
Today, we circle back on a small development firm called Savara for the first time in over two years. Its primary drug candidate is being developed for a rare affliction that has no approved therapies and has a pivotal readout coming up in the second quarter of 2024. An update investment analysis around Savara follows in the paragraphs below. Read More
Posted: Jul 16 2023, 11:50
Author Name: Seeking Alpha
Views: 102279

SVRA News  

Savara: A Speculative Play

By Seeking Alpha
July 16, 2023

Savara: A Speculative Play

Today, we circle back on a small development firm called Savara for the first time in over two years. Its primary drug candidate is being developed fo more_horizontal

Savara to Present at the Jefferies Healthcare Conference

By Business Wire
June 2, 2023

Savara to Present at the Jefferies Healthcare Conference

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today ann more_horizontal

Why Shares of Savara Jumped on Tuesday

By The Motley Fool
May 16, 2023

Why Shares of Savara Jumped on Tuesday

Savara is a clinical-stage pharmaceutical company with no revenue. The company expects a top-line readout on molgramostim in the second quarter of 202 more_horizontal

Savara to Present at the Oppenheimer 33rd Annual Healthcare Conference

By Business Wire
March 6, 2023

Savara to Present at the Oppenheimer 33rd Annual Healthcare Conference

AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today ann more_horizontal

Why Shares of Savara Soared This Week

By The Motley Fool
January 27, 2023

Why Shares of Savara Soared This Week

The clinical-stage biopharmaceutical company focuses on therapies to treat rare respiratory diseases. more_horizontal


Search within

Pages Search Results: